For a 45‑year‑old Hispanic male with newly diagnosed diabetes (A1C 14.5 %), creatinine 0.68 mg/dL, eGFR >90 mL/min/1.73 m², weight 98.4 kg, not in diabetic ketoacidosis, and recent insulin drip rates of 2, 2, 3, 2, 2, 3 units over the past 6 hours, what should his once‑daily basal insulin (insulin glargine, Lantus) dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Basal Insulin Dosing for Newly Diagnosed Type 2 Diabetes

For this patient, initiate Lantus at 20 units once daily at bedtime, with an insulin sensitivity factor (ISF) of 1:50 and an insulin-to-carbohydrate ratio (ICR) of 1:10.

Rationale for Basal Insulin Dose

Your patient's insulin drip averaged 2.3 units/hour over the past 6 hours, totaling approximately 14 units over that period. Extrapolated to 24 hours, this suggests a total daily insulin requirement of approximately 55 units. However, since he is not in DKA and has newly diagnosed type 2 diabetes with preserved renal function, we should use a more conservative conversion approach 1, 2.

Calculation Method:

  • Total daily insulin requirement estimate: 0.2 units/kg × 98.4 kg = 19.7 units/day
  • Basal insulin component: Approximately 50% of total daily dose = ~10 units
  • However, given his recent insulin drip requirements and A1C of 14.5%, start at the higher end: 20 units once daily

The ADA 2025 guidelines recommend starting basal insulin at either 10 units per day OR 0.1-0.2 units/kg per day 1. The FDA label for Lantus specifically states that for type 2 diabetes patients not currently on insulin, the recommended starting dose is 10 units (or 0.2 units/kg) once daily 2. Given his significant hyperglycemia (A1C 14.5%) and recent insulin requirements on drip, starting at 0.2 units/kg (approximately 20 units) is appropriate.

Insulin Sensitivity Factor (ISF)

Use the "1500 Rule" for rapid-acting insulin or "1800 Rule" for regular insulin:

  • 1500 ÷ estimated total daily insulin dose (50 units) = 1:30
  • However, for newly diagnosed patients with preserved renal function and to minimize hypoglycemia risk, start more conservatively at 1:50

This means 1 unit of rapid-acting insulin will lower blood glucose by approximately 50 mg/dL.

Insulin-to-Carbohydrate Ratio (ICR)

Use the "500 Rule":

  • 500 ÷ estimated total daily insulin dose (50 units) = 1:10

This means 1 unit of rapid-acting insulin covers 10 grams of carbohydrate.

Titration Strategy

Following ADA 2025 guidelines 1:

  • Set fasting plasma glucose goal: 80-130 mg/dL
  • Titration algorithm: Increase Lantus by 2 units every 3 days until fasting glucose reaches goal without hypoglycemia
  • For hypoglycemia: If blood glucose <70 mg/dL without clear cause, reduce dose by 10-20% (2-4 units)
  • Reassess every 3-6 months to avoid therapeutic inertia

Important Considerations

Renal Function

His eGFR >90 mL/min/1.73 m² is excellent, requiring no dose adjustment 2, 3. Insulin glargine has not been extensively studied in renal impairment, but his normal kidney function eliminates this concern.

Timing and Administration

  • Administer Lantus once daily at the same time each day (typically bedtime) 2
  • Do NOT mix with other insulins - Lantus must be given separately 2
  • Rotate injection sites within the same region (abdomen, thigh, or deltoid) 2

Common Pitfalls to Avoid

  1. Do not use Lantus intravenously - the usual subcutaneous dose given IV could cause severe hypoglycemia 2
  2. Do not dilute or mix Lantus with any other insulin or solution 2
  3. Monitor for nocturnal hypoglycemia - although Lantus has a flat profile, risk exists in the first 4 weeks 4
  4. Ensure basal insulin is never stopped - even if patient becomes NPO, continue basal insulin (unlike prandial insulin) 5

Prandial Insulin Coverage

If adding mealtime insulin becomes necessary (if A1C remains >7% after basal optimization):

  • Start with 4 units of rapid-acting insulin before the largest meal 1
  • Alternatively, use 10% of basal dose (2 units in this case, though 4 units is more practical)
  • Titrate by 1-2 units or 10-15% based on postprandial glucose readings 1

Monitoring Requirements

  • Daily fasting glucose for titration
  • Pre-meal and 2-hour postprandial glucose if adding prandial insulin
  • A1C every 3 months until at goal, then every 6 months 1
  • Prescribe glucagon for emergency hypoglycemia treatment 1

This approach balances aggressive glycemic control (given his A1C of 14.5%) with safety, using evidence-based starting doses and titration algorithms that minimize hypoglycemia risk while achieving target glucose levels 1, 2.

References

Research

Insulin glargine: a new long-acting insulin product.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002

Related Questions

In an 84‑year‑old woman with preserved renal function (creatinine 0.49 mg/dL, eGFR >90 mL/min), hemoglobin A1c 14.8 % and weight 59.6 kg who is currently on basal insulin glargine 11 U daily with an insulin‑to‑carbohydrate ratio of 1:15 and an insulin sensitivity factor of 1:50 but refuses insulin at discharge, what non‑insulin treatment options are appropriate?
In a 62-year-old woman with a hemoglobin A1c of 6.5% (improved from 6.9% with diet and exercise) and a creatinine clearance of 51 mL/min, should pharmacologic therapy for diabetes be initiated?
For a 74‑year‑old male weighing 67.6 kg with an estimated glomerular filtration rate of approximately 60 mL/min, who is on Lantus (insulin glargine) 18 units at 09:00, has an insulin sensitivity factor of 25 mg/dL per unit, receives prednisone 10 mg at 08:00 and dexamethasone 10 mg at 14:00, and has recent insulin‑drip glucose data, what should his morning Lantus dose, insulin sensitivity factor, and insulin‑to‑carbohydrate ratio be while dexamethasone remains active?
For a 61-year-old male weighing 53.1 kg with pancreatogenic diabetes and normal renal function (creatinine 0.74 mg/dL, GFR > 90 mL/min) who is on insulin glargine (Lantus) 15 units daily, insulin‑sensitivity factor 50 mg/dL per unit, and insulin‑to‑carbohydrate ratio 15 g per unit, and is now on a clear‑liquid diet after an insulin drip, what should his basal insulin dose, insulin‑sensitivity factor, and carbohydrate‑to‑insulin ratio be?
A 46-year-old woman with a current hemoglobin A1c of 6.2% (previously 11.6% nine months ago) has fasting glucose around 150 mg/dL; should she continue taking 15 units of insulin glargine (Lantus) at bedtime and 7 units of insulin lispro with each meal?
Which laboratory tests should be ordered for a patient with new‑onset hallucinations who has diabetes, chronic kidney disease, and hyperlipidemia?
In a patient with Graves disease who is clinically and biochemically euthyroid on carbimazole 5 mg twice daily, what is the best predictor of remission?
For a 64-year-old man with bleeding radiation proctitis, is argon plasma coagulation (APC) the best treatment, or are other therapies or conservative management preferable?
In an elderly woman with hypertension, hypercholesterolemia, a history of cancer, moderately reduced renal function, elevated uric acid, slightly low prothrombin activity, and an isolated increase in carcinoembryonic antigen (CEA), what diagnostic and therapeutic protocol is recommended?
What are the recommended dosing adjustments and safety considerations for orphenadrine in patients with impaired renal function?
Can a female patient who has achieved her goal weight remain on 10 mg Zepbound (tirzepatide)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.